Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

  • Lima, Nátalia da Silva
  • Fernández Fondevila, Marcos
  • Novoa Deaño, Eva María
  • Buqué, Xabier
  • Mercado Gómez, María
  • Gallet, Sarah
  • González Rellán, María Jesús
  • Fernández Paz, Uxía
  • Loyens, Anne
  • García Vence, María
  • Chantada Vázquez, María del Pilar
  • Bravo López, Susana Belén
  • Marañón Barnusell, Patricia
  • Senra Viñas, Ana
  • Escudero Pérez, Adriana
  • Leiva Arjona, Magdalena
  • Guallar Artal, Diana
  • Fidalgo Pérez, Miguel Ángel
  • Gomes, Pedro
  • Claret, Marc
  • Sabio Buzo, Guadalupe
  • Varela Rey, Marta María
  • Cardoso Delgado, Teresa
  • Montero Vallejo, Rocío
  • Ampuero, Javier
  • López Pérez, Miguel A.
  • Diéguez González, Carlos
  • Herrero, Laura
  • Serra Cucurull, Dolors
  • Schwaninger, Markus
  • Prevot, Vincent
  • Gallego-Durán, Rocío
  • Romero-Gómez, Manuel
  • Iruzubieta, Paula
  • Crespo García, Javier
  • Martínez Chantar, María Luz
  • García Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Aspichueta, Patricia
  • Nogueiras Pozo, Rubén
Non-alcoholic fatty liver disease (NAFLD) is a major health threat in both developed and developing countries and is a precursor of the more advanced liver diseases, including non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Currently, understanding the multiple and complex molecular pathways implicated in NAFLD onset and progression is a major priority. The transcription factor p63, which belongs to a family comprising p53, p63, and p73,1 is one of many factors that contributes to the development of liver steatosis. The role of p63 as a tumor suppressor and in cell maintenance and renewal is well studied, but we have recently reported that it is also relevant in the control of lipid metabolism.2 p63 encodes multiple isoforms that can be grouped into 2 categories; isoforms with an acidic transactivation domain (TA) and those without this domain (domain negative). The TAp63α isoform is elevated in the liver of animal models of NAFLD as well as in liver biopsies from obese patients with NAFLD. Furthermore, downregulation of p63α in the liver attenuates liver steatosis in diet-induced obese (DIO) mice, while the activation of TAp63α increases hepatic fat content, mediated by the activation of IKKβ and endoplasmic reticulum stress.2 A specialized form of autophagy that degrades lipid droplets, termed “lipophagy”, is a major pathway of lipid mobilization in hepatocytes. Lipophagy is elevated in hepatoma cells upon exposure to free fatty acids,3 and reduces the fatty acid load in mouse hepatocytes.4 Its impairment has been associated with the development of fatty liver and insulin resistance3,5; in contrast, the autophagic flux is increased during the activation of hepatic stellate cells.6 In the present study, we used an unbiased proteomics approach to gain insight into novel proteins modulating lipid metabolism in the liver of mice with genetic knockdown or overexpression of TAp63α. We found that autophagy-related gene 3 (ATG3) was upregulated by TAp63α activation and downregulated after p63α inhibition. ATG3 is elevated in several animal models of NAFLD and in the liver of patients with NAFLD. Genetic overexpression of ATG3 increased the lipid load in hepatocytes, while its repression alleviated TAp63α- and diet-induced steatosis. ATG3 exerted its role in lipid metabolism by regulating SIRT1 and mitochondrial function. Collectively, these findings identify ATG3 as a novel factor implicated in the development of steatosis
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

  • Serrano Maciá, Marina
  • Simón, Jorge
  • González Rellán, María Jesús
  • Azkargorta, Mikel
  • Goikoetxea-Usandizaga, Naroa
  • Lopitz Otsoa, Fernando
  • Sáenz de Urturi, Diego
  • Rodríguez Agudo, Rubén
  • Lachiondo-Ortega, Sofia
  • Mercado Gómez, María
  • Gutiérrez de Juan, Virginia
  • Bizkarguenaga-Uribiarte, Maider
  • Fernández-Ramos, David
  • Buqué, Xabier
  • Baselli, Guido Alessandro
  • Valenti, Luca
  • Iruzubieta, Paula
  • Crespo, Javier
  • Villa, Erica
  • Banales, Jesus
  • Avila, Matias A.
  • Marin, Jose
  • Aspichueta, Patricia
  • Sutherland, James D.
  • Barrio, Rosa
  • Mayor, Ugo
  • Elortza, Felix
  • Xirodimas, Dimitris
  • Nogueiras Pozo, Rubén
  • Delgado, Teresa
  • Martínez Chantar, María Luz
Objective: Neddylation is a druggable and reversible ubiquitin-like post-translational modification upregulated in many diseases, including liver fibrosis, hepatocellular carcinoma, and more recently, non-alcoholic fatty liver disease (NAFLD). Herein, we propose to address the effects of neddylation inhibition and the underlying mechanisms in pre-clinical models of NAFLD. Methods: Hepatic neddylation measured by immunohistochemical analysis and NEDD8 serum levels measured by ELISA assay were evaluated in NAFLD clinical and pre-clinical samples. The effects of neddylation inhibition by using a pharmacological small inhibitor, MLN4924, or molecular approaches were assessed in isolated mouse hepatocytes and pre-clinical mouse models of diet-induced NAFLD, male adult C57BL/6 mice, and the AlfpCre transgenic mice infected with AAV-DIO-shNedd8. Results: Neddylation inhibition reduced lipid accumulation in oleic acid-stimulated mouse primary hepatocytes and ameliorated liver steatosis, preventing lipid peroxidation and inflammation in the mouse models of diet-induced NAFLD. Under these conditions, increased Deptor levels and the concomitant repression of mTOR signaling were associated with augmented fatty acid oxidation and reduced lipid content. Moreover, Deptor silencing in isolated mouse hepatocytes abolished the anti-steatotic effects mediated by neddylation inhibition. Finally, serum NEDD8 levels correlated with hepatic neddylation during the disease progression in the clinical and pre-clinical models. Conclusions: Overall, the upregulation of Deptor, driven by neddylation inhibition, is proposed as a novel effective target and therapeutic approach to tackle NAFLD
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

  • Simón, Jorge
  • Goikoetxea-Usandizaga, Naroa
  • Serrano-Maciá, Marina
  • Fernández-Ramos, David
  • Sáenz de Urturi, Diego
  • Gruskos, Jessica J.
  • Fernández-Tussy, Pablo
  • Lachiondo-Ortega, Sofía
  • González-Recio, Irene
  • Rodríguez-Agudo, Rubén
  • Gutiérrez de Juan, Virginia
  • Rodríguez-Iruretagoyena, Begoña
  • Varela-Rey, Marta
  • Gimenez-Mascarell, Paula
  • Mercado-Gómez, María
  • Gómez-Santos, Beatriz
  • Fernández-Rodríguez, Carmen
  • Lopitz-Otsoa, Fernando
  • Bizkarguenaga, Maider
  • Dames, Sibylle
  • Schaeper, Ute
  • Martín, Franz
  • Sabio, Guadalupe
  • Iruzubieta, Paula
  • Crespo, Javier
  • Aspichueta, Patricia
  • Chu, Kevan H.-Y.
  • Buccella, Daniela
  • Martín, César
  • Cardoso Delgado, Teresa de Jesús
  • Martínez-Cruz, Luis Alfonso
  • Martínez-Chantar, María Luz
Background & Aims: Perturbations of intracellular magnesium (Mg) homeostasis have implications for cell physiology. The cyclin M family, CNNM, perform key functions in the transport of Mg across cell membranes. Herein, we aimed to elucidate the role of CNNM4 in the development of non-alcoholic steatohepatitis (NASH). Methods: Serum Mg levels and hepatic CNNM4 expression were characterised in clinical samples. Primary hepatocytes were cultured under methionine and choline deprivation. A 0.1% methionine and choline-deficient diet, or a choline-deficient high-fat diet were used to induce NASH in our in vivo rodent models. Cnnm4 was silenced using siRNA, in vitro with DharmaFECT and in vivo with Invivofectamine® or conjugated to N-acetylgalactosamine. Results: Patients with NASH showed hepatic CNNM4 overexpression and dysregulated Mg levels in the serum. Cnnm4 silencing ameliorated hepatic lipid accumulation, inflammation and fibrosis in the rodent NASH models. Mechanistically, CNNM4 knockdown in hepatocytes induced cellular Mg accumulation, reduced endoplasmic reticulum stress, and increased microsomal triglyceride transfer activity, which promoted hepatic lipid clearance by increasing the secretion of VLDLs. Conclusions: CNNM4 is overexpressed in patients with NASH and is responsible for dysregulated Mg transport. Hepatic CNNM4 is a promising therapeutic target for the treatment of NASH. Lay summary: Cyclin M4 (CNNM4) is overexpressed in non-alcoholic steatohepatitis (NASH) and promotes the export of magnesium from the liver. The liver-specific silencing of Cnnm4 ameliorates NASH by reducing endoplasmic reticulum stress and promoting the activity of microsomal triglyceride transfer protein., Ministerio de Ciencia e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (for JS and MLM-C); Instituto de Salud Carlos III, Proyectos de Investigación en Salud DTS20/00138 (for JS and MLM-C); Departamento de Industria del Gobierno Vasco (for MLM-C); Ministerio de Ciencia, Innovación y Universidades MICINN: SAF2017-87301-R and RTI2018-096759-A-100 integrado en el Plan Estatal de Investigación Cientifica y Técnica y Innovación, cofinanciado con Fondos FEDER (for MLM-C and TCD, respectively); BIOEF (Basque Foundation for Innovation and Health Research); EITB Maratoia BIO15/CA/014; Asociación Española contra el Cáncer (MLM-C, TCD); Fundación Científica de la Asociación Española Contra el Cancer (AECC Scientific Foundation) Rare Tumor Calls 2017 (for MLM); La Caixa Foundation Program (for MLM); Fundacion BBVA UMBRELLA project (for MLM); BFU2015-70067-REDC, BFU2016-77408-R, and BES-2017- 080435 (MINECO / FEDER, UE) and the FIGHT-CNNM2 project from the EJP RD Joint Transnational Call (JTC2019) (Ref. AC19/ 00073) (for LAM-C); RTI2018-095134-B-100 and Grupos de Investigación del Sistema Universitario Vasco (IT971-16) (for PA); National Institutes of Health under grant CA217817 (for DB); AGL2014-54585-R, AGL-2017-86927-R and EQC2018-004897-P from MINECO; PC0148-2016-0149 and PAI-BIO311 from Junta de Andalucía (for FM). Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. We thank Silence Therapeutics plc. for the financial support provided. We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV- 2016-0644).